Crinetics Pharmaceuticals, Inc. (CRNX) — 10-Q Filings

10-Q Filings (6)

• Crinetics' Losses Widen Amid Soaring R&D, SG&A Costs — Nov 6, 2025 Risk: high
  Crinetics Pharmaceuticals, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $342.5 million, up from $217.
• Crinetics' Q2 Loss Widens Amid Soaring R&D Costs — Aug 7, 2025 Risk: high
  Crinetics Pharmaceuticals, Inc. reported a net loss of $70.8 million for the three months ended June 30, 2025, an increase from a net loss of $57.2 million for
• Crinetics Pharmaceuticals Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  Crinetics Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key finan
• Crinetics Pharmaceuticals Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Crinetics Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates. Key f
• Crinetics Pharmaceuticals Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Crinetics Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and results of operations, i
• Crinetics Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  Crinetics Pharmaceuticals, Inc. (CRNX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Crinetics Pharmaceuticals, Inc. filed a 10-Q report for the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX